Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$110.45 USD
+0.42 (0.38%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $110.46 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$110.45 USD
+0.42 (0.38%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $110.46 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth F Momentum B VGM
Zacks News
ImmunoGen to Push Leukemia Candidate into Phase I Trial
by Zacks Equity Research
ImmunoGen (IMGN) plans to move its leukemia candidate, IMGN632, into phase I study before the year ends. Also, the FDA has completed the safety review of its IND application for IMGN632.
Genocea Biosciences (GNCA) Jumps: Stock Rises 24.8%
by Zacks Equity Research
Genocea Biosciences (GNCA) was a big mover last session, as the company saw its shares rise almost 25% on the day amid huge volumes.
Rigel Pharmaceuticals (RIGL) in Focus: Stock Moves 12.1% Higher
by Zacks Equity Research
Rigel Pharmaceuticals (RIGL) was a big mover last session, as the company saw its shares rise more than 12% on the day amid huge volumes.
Synergy Pharmaceuticals (SGYP) Surges: Stock Moves 12.1% Higher
by Zacks Equity Research
Synergy Pharmaceuticals (SGYP) was a big mover last session, as the company saw its shares rise more than 12% on the day amid huge volumes.
3 Pharma/Biotech Sector Bargains for a Healthy Portfolio
by Zacks Equity Research
The biotech sector has turned around after its dismal performance in 2016 as uncertainty surrounding drug pricing control subsides. A few stocks are however still undervalued, which may gain going ahead.
Jazz Pharmaceuticals, O'Reilly Automotive and Tesla highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Jazz Pharmaceuticals, O'Reilly Automotive and Tesla highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Jazz Pharmaceuticals (JAZZ)
by Kevin Cook
Trading at just 11X next year's $13 EPS, this innovator is just getting started fighting cancer with new FDA approvals and partnerships
Zacks.com featured highlights include Lantheus Holdings, Jazz Pharmaceuticals, Gray Television, Aetna and Uniti Group
by Zacks Equity Research
Zacks.com featured highlights include Lantheus Holdings, Jazz Pharmaceuticals, Gray Television, Aetna and Uniti Group
Immunogen Inks Deal With Jazz Pharma to Develop ADC Molecule
by Zacks Equity Research
ImmunoGen (IMGN) and Jazz Pharma announced a strategic collaboration to develop and commercialize antibody-drug conjugate products.
ImmunoGen (IMGN) in Focus: Stock Moves 17.3% Higher
by Zacks Equity Research
ImmunoGen (IMGN) was a big mover last session, as the company saw its shares rise over 17% on the day amid huge volumes.
5 Excellent Value Stocks Based on Low PEG Ratio
by Zacks Equity Research
While P/E alone fails to identify a true value stock, PEG helps find the intrinsic value of a stock.
Enanta Pharmaceuticals (ENTA) Looks Good: Stock Adds 9.6% in Session
by Zacks Equity Research
Enanta Pharmaceuticals, Inc. (ENTA) was a big mover last session, as the company saw its shares rise over 9% on the day.
Ironwood Pharma's Combination Gout Drug Gets FDA Approval
by Zacks Equity Research
Ironwood Pharmaceuticals, Inc. (IRWD) announced that the FDA has approved Duzallo for the treatment of hyperuricemia in patients with uncontrolled gout.
Rally Set to Resume: Buy These 5 Value Picks on the Dip
by Swarup Gupta
Morgan Stanley believes that conditions for a Bull Run remain in place.
Jazz Pharmaceuticals Arm Announces $500M Senior Notes Offer
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) announces private offering of exchangeable senior notes to qualified institutional buyers to raise proceeds and repay debt.
Endo International (ENDP) Jumps: Stock Rises 6.9%
by Zacks Equity Research
Endo International (ENDP) was a big mover last session, as the company saw its shares rise almost 7% on the day amid huge volumes.
Jounce Therapeutics (JNCE) Jumps: Stock Moves 7.4% Higher
by Zacks Equity Research
Jounce Therapeutics, Inc. (JNCE) moved big last session, as its shares jumped over 7% on the day.
Jazz Pharma (JAZZ) Q2 Earnings & Revenues Miss, View Intact
by Zacks Equity Research
Jazz Pharma's (JAZZ) earnings and revenues miss estimates. However, the top line rises year over year owing to higher sales of the company's marketed drug, Xyrem.
Can Jazz Pharma (JAZZ) Spring a Surprise in Q2 Earnings?
by Zacks Equity Research
Jazz Pharma's (JAZZ) lead drug, Xyrem, is likely to deliver a strong performance in Q2, thanks to label expansion efforts.
AVEO's Kidney Cancer Candidate Gets CHMP Recommendation
by Zacks Equity Research
AVEO Pharmaceuticals, Inc. (AVEO) announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its lead candidate, Fotivda (tivozanib), for the treatment of advanced renal cell carcinoma (RCC).
Why Is Jazz Pharmaceuticals (JAZZ) Down 3.3% Since the Last Earnings Report?
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jazz Pharma Sleep Disorder Candidate Positive in Phase III
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) announced positive efficacy results from studies evaluating its lead pipeline candidate, JZP-110, in adult patients with excessive sleepiness (ES) associated with narcolepsy and obstructive sleep apnea (OSA).
Jazz Pharmaceuticals' Vyxeos NDA Granted Priority Review
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) announced that the New Drug Application (NDA) for its experimental leukemia candidate Vyxeos has been accepted for priority review by the FDA.
BioLineRx Makes Regulatory Submission for Trial of BL-8040
by Zacks Equity Research
BioLineRx Ltd. (BLRX) announced that it has submitted a regulatory filing required to start a phase Ib study for BL-8040 in combination with Roche Group's (RHHBY) Tecentriq (atezolizumab).
Jazz Pharmaceuticals (JAZZ) Misses Q1 Earnings & Sales
by Zacks Equity Research
Jazz Pharmaceuticals Public Limited Company (JAZZ) reported first-quarter 2017 earnings of $1.41 per share, which narrowly missed the Zacks Consensus Estimate of $1.42.